STAT

In France, it’s illegal for consumers to order a DNA spit kit. Activists are fighting over lifting the ban

Under French law, having a direct-to-consumer genetic test can, technically speaking, put you at risk of being fined about $4,140.
Source: ERIC FEFERBERG/AFP via Getty Images

PARIS — From scanning her resume, you’d never guess Nathalie Jovanovic-Floricourt was an expert enabler of criminal activity. For years, she’d fretted over photo quality and page layout for publishing houses. Since 2007, she’s worked in communications for a bank — hardly a bastion of activist law-breakers. She lives in a quiet town an hour’s train ride away from Paris.

Then again, her underworld of choice is more socially acceptable than most: Jovanovic-Floricourt is a self-styled fixer for black-market genetic tests. She’s not a dealer. She doesn’t import spit-in-a-cup kits on anyone else’s behalf. She’s just tried out a bunch of different companies for herself — ordering them to an American package forwarding firm, say, if the manufacturer won’t ship directly to France — and helped others to do the same through talks, salons, books, and blog posts. Often, she says, fellow genealogists come to her with questions about their results.

“In doing these genetic ancestry tests, we’re risking a fine of 3,750 euros” — about $4,140 — “at least in theory,” she said one afternoon in late

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks